Top

Published in:

01-06-2011 | SSIEM Symposium 2010

High-throughput structural biology of metabolic enzymes and its impact on human diseases

Authors: Wyatt W. Yue, Udo Oppermann

Published in: Journal of Inherited Metabolic Disease | Issue 3/2011

Abstract

The Structural Genomics Consortium (SGC) is a public-private partnership that aims to determine the three-dimensional structures of human proteins of medical relevance and place them into the public domain without restriction. To date, the Oxford Metabolic Enzyme Group at SGC has deposited the structures of more than 140 human metabolic enzymes from diverse protein families such as oxidoreductases, hydrolases, oxygenases and fatty acid transferases. A subset of our target proteins are involved in the inherited disorders of carbohydrate, fatty acid, amino acid and vitamin metabolism. This article will provide an overview of the structural data gathered from our high-throughput efforts and the lessons learnt in the structure-function relationship of these enzymes, small molecule development and the molecular basis of disease mutations.

Abagyan R, Lee WH, Raush E, Budagyan L, Totrov M, Sundstrom M, Marsden BD (2006) Disseminating structural genomics data to the public: from a data dump to an animated story. Trends Biochem Sci 31:76–78PubMedCrossRef

Banerjee R, Gherasim C, Padovani D (2009) The tinker, tailor, soldier in intracellular B12 trafficking. Curr Opin Chem Biol 13:484–491PubMedCrossRef

Bayley JP, Launonen V, Tomlinson IP (2008) The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 9:20PubMedCrossRef

Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575–584PubMedCrossRef

Capriotti E, Fariselli P, Casadio R (2004) A neural-network-based method for predicting protein stability changes upon single point mutations. Bioinformatics 20(Suppl 1):i63–i68PubMedCrossRef

Cottingham K (2008) The structural genomics consortium makes its presence known. J Proteome Res 7:5073PubMedCrossRef

Dessailly BH, Nair R, Jaroszewski L, Fajardo JE, Kouranov A, Lee D, Fiser A, Godzik A, Rost B, Orengo C (2009) PSI-2: structural genomics to cover protein domain family space. Structure 17:869–881PubMedCrossRef

Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RG, Oppermann U, Kavanagh KL (2008) Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 51:2187–2195PubMedCrossRef

Edwards A (2009) Large-scale structural biology of the human proteome. Annu Rev Biochem 78:541–568PubMedCrossRef

Froese DS, Gravel RA (2010) Genetic disorders of vitamin B12 metabolism: eight complementation groups—eight genes. Expert Rev Mol Med 12:e37PubMedCrossRef

Froese DS, Kochan G, Muniz JR, Wu X, Gileadi C, Ugochukwu E, Krysztofinska E, Gravel RA, Oppermann U, Yue WW (2010) Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation. J Biol Chem 285:38204–38213PubMedCrossRef

Grabowski M, Chruszcz M, Zimmerman MD, Kirillova O, Minor W (2009) Benefits of structural genomics for drug discovery research. Infect Disord Drug Targets 9:459–474PubMedCrossRef

Joachimiak A (2009) High-throughput crystallography for structural genomics. Curr Opin Struct Biol 19:573–584PubMedCrossRef

Johansson C, Roos AK, Montano SJ, Sengupta R, Filippakopoulos P, Guo K, von Delft F, Holmgren A, Oppermann U, Kavanagh KL (2010) The crystal structure of human GLRX5: iron-sulfur cluster co-ordination, tetrameric assembly and monomer activity. Biochem J 433(2):303–311

Kang TS, Stevens RC (2009) Structural aspects of therapeutic enzymes to treat metabolic disorders. Hum Mutat 30:1591–1610PubMedCrossRef

Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U (2006) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829–7834PubMedCrossRef

Kavanagh KL, Jornvall H, Persson B, Oppermann U (2008) The SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes. Cell Mol Life Sci 65:3895–3906PubMedCrossRef

Kochan G, Pilka ES, von Delft F, Oppermann U, Yue WW (2009) Structural snapshots for the conformation-dependent catalysis by human medium-chain acyl-coenzyme A synthetase ACSM2A. J Mol Biol 388:997–1008PubMedCrossRef

Lee WH, Atienza-Herrero J, Abagyan R, Marsden BD (2009) SGC–structural biology and human health: a new approach to publishing structural biology results. PLoS ONE 4:e7675PubMedCrossRef

Lukacik P, Kavanagh KL, Oppermann U (2006) Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 248:61–71PubMedCrossRef

Muller S, Weigelt J (2010) Open-access public-private partnerships to enable drug discovery—new approaches. IDrugs 13:175–180PubMed

Ng PC, Henikoff S (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80PubMedCrossRef

Ng SS, Kavanagh KL, McDonough MA, Butler D, Pilka ES, Lienard BM, Bray JE, Savitsky P, Gileadi O, von Delft F, Rose NR, Offer J, Scheinost JC, Borowski T, Sundstrom M, Schofield CJ, Oppermann U (2007) Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature 448:87–91PubMedCrossRef

Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293–322PubMedCrossRef

Page R, Stevens RC (2004) Crystallization data mining in structural genomics: using positive and negative results to optimize protein crystallization screens. Methods 34:373–389PubMedCrossRef

Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, Favia AD, Duarte RG, Jornvall H, Kavanagh KL, Kedishvili N, Kisiela M, Maser E, Mindnich R, Orchard S, Penning TM, Thornton JM, Adamski J, Oppermann U (2009) The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact 178:94–98PubMedCrossRef

Picaud SS, Muniz JR, Kramm A, Pilka ES, Kochan G, Oppermann U, Yue WW (2009) Crystal structure of human carbonic anhydrase-related protein VIII reveals the basis for catalytic silencing. Proteins 76:507–511PubMedCrossRef

Pojer F, Ferrer JL, Richard SB, Nagegowda DA, Chye ML, Bach TJ, Noel JP (2006) Structural basis for the design of potent and species-specific inhibitors of 3-hydroxy-3-methylglutaryl CoA synthases. Proc Natl Acad Sci USA 103:11491–11496PubMedCrossRef

Savitsky P, Bray J, Cooper CD, Marsden BD, Mahajan P, Burgess-Brown NA, Gileadi O (2010) High-throughput production of human proteins for crystallization: the SGC experience. J Struct Biol 172:3–13PubMedCrossRef

Shafqat N, Turnbull A, Zschocke J, Oppermann U, Yue WW (2010) Crystal structures of human HMG-CoA synthase isoforms provide insights into inherited ketogenesis disorders and inhibitor design. J Mol Biol 398:497–506PubMedCrossRef

Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN (2009) The human gene mutation database: 2008 update. Genome Med 1:13PubMedCrossRef

Steward RE, MacArthur MW, Laskowski RA, Thornton JM (2003) Molecular basis of inherited diseases: a structural perspective. Trends Genet 19:505–513PubMedCrossRef

Thusberg J, Vihinen M (2009) Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat 30:703–714PubMedCrossRef

Weigelt J (2010) Structural genomics-impact on biomedicine and drug discovery. Exp Cell Res 316:1332–1338PubMedCrossRef

Wu X, Lukacik P, Kavanagh KL, Oppermann U (2007) SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation. Mol Cell Endocrinol 265–266:71–76PubMedCrossRef

Title: High-throughput structural biology of metabolic enzymes and its impact on human diseases
Authors: Wyatt W. Yue
Udo Oppermann
Publication date: 01-06-2011
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 3/2011
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-011-9296-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Disorders of bile acid synthesis

Newborn screening for congenital hypothyroidism in very-low-birth-weight babies: the need for a second test

Protein structure reports in JIMD - an important enhancement of journal scope

Transition of young adults with phenylketonuria from pediatric to adult care

Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?

Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials